Empower Clinics: New COVID-19 Testing Products

May 4, 2021

Providing body and mind wellness for over 200,000 patients

Empower provides body and mind wellness for more than 200,000 patients through its clinics in the United States & Canada, a telemedicine platform and a world-class medical diagnostics laboratory in Texas.

Supported by an experienced leadership team, Empower is also aggressively growing its clinical and digital presence across the US and Canada. Its Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of its patients. They also provide long term value for its shareholders.

Furthermore, Empower has a particular focus right now on COVID-19 and bringing to market new novel COVID-19 testing products.

The company already had all of the operational pieces to start offering COVID-19 testing. Moreover, they realized that ultimately there was a better margin and revenue by owning a lab. " We decided it'd be better to acquire rather than open a lab. And we started looking around for appropriate lab partners. We landed on Kai Medical Laboratory out of Dallas, Texas," says Chairman and CEO, Steven McAuley.

COVID-19 Testing Kits

When COVID happened, Kai Medical Laboratory knew they needed to find a solution to be able to triage patients and test them so that that they could get treated. "It was kind of a no-brainer to go with a saliva device collection kit," says President, Kai Medical Laboratory, Yoshi Tyler.

That Kai Saliva at home COVID-19 test, kickstarted a focus on direct-to-consumer self-testing. With Empower’s financial backing, an e-commerce store has been launched. KaiTests.com and KaiTests.ca are the platforms in the U.S. and Canada that will offer a wide range of medical testing products.

For more information on Empower Clinics Inc. (CSE: CBDT) please click on the request investor info button.

You might also like

Healthcare
Lexaria Bioscience: Revolutionizing GLP-1 Drug Delivery with Patented Oral Platform

Lexaria Bioscience is setting new standards in drug delivery with its patented DehydraTECH™ oral technology, optimizing absorption for GLP-1 and other high-demand drugs.

Healthcare
Lexaria Bioscience: Advancing GLP-1 Drug Delivery with DehydraTECH™ Technology

Lexaria Bioscience’s DehydraTECH™ technology aims to redefine oral drug delivery, focusing on faster absorption and improved efficacy, with a promising impact on the GLP-1 pharmaceutical market.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, The Globe and Mail, YouTube and more!